Enrolling by invitationPHASE2, PHASE3NCT05248659

Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy

Studying IgA Nephropathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Intervention
Sibeprenlimab 400 mg s.c. Q4weeks(drug)
Enrollment
600 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2028

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05248659 on ClinicalTrials.gov

Other trials for IgA Nephropathy

Additional recruiting or active studies for the same condition.

See all trials for IgA Nephropathy →

← Back to all trials